In Brief
Although mitochondrial diseases have diverse causes, they are all characterized by defective oxidative phosphorylation. Civiletto et al. show that overexpression of the mitochondria-shaping protein OPA1, which improves respiratory chain efficiency, improves the phenotypes of two pre-clinical models of defective mitochondrial bioenergetics.
INTRODUCTION
Mutations in mitochondrial DNA (mtDNA), and in the vast repertoire of nuclear genes that converge on the formation and function of the mitochondrial respiratory chain (MRC), are responsible for primary ''mitochondrial disorders,'' a group of highly heterogeneous conditions, hallmarked by faulty oxidative phosphorylation (OXPHOS) , that can affect any organ, at any age, and by any mode of transmission (Koopman et al., 2012) . When taken as a whole, mitochondrial disorders are among the most frequent genetic diseases, affecting >1 in 5,000 individuals in the European population (Elliott et al., 2008) . Despite substantial progress in mitochondrial medicine, the complexity of mitochondrial biology and genetics still constitutes a major challenge for understanding the mechanistic basis of mitochondrial disorders and explains, at least in part, their huge clinical and biochemical variability, which is also a major hurdle toward effective treatment. However, the development of ''general'' therapeutic strategies, extendable to diverse disease-associated OXPHOS defects, is now a realistic goal, based on rapidly expanding knowledge of the molecular mechanisms underpinning mitochondrial biogenesis, quality control, and signaling pathways. Several of these mechanisms are related to the control of mitochondrial shape and organization of the mitochondrial network.
Mitochondria are highly dynamic organelles that fuse and divide to adapt their structure and morphology to the energetic needs of the cell (Kasahara and Scorrano, 2014) . Dynaminrelated GTPases located on the inner and outer mitochondrial membranes (IMMs and OMMs) control the fission and fusion processes (Griparic and van der Bliek, 2001) . Mitochondrial fission and fusion regulate a number of cellular processes, including organelle distribution during cell proliferation, bioenergetics proficiency, mitochondrial calcium flux, mitochondrial apoptosis, autophagy, and even complex morphogenetic processes such as the formation of dendritic spines (Kasahara and Scorrano, 2014) . Fission is regulated by Dynamin-Related Protein 1 (DRP1) and by its OMM partners Fission 1 (FIS1), Mitochondrial Fission Factor (MFF), and Mitochondrial Division (MID) 49 and 51; fusion is controlled by the OMM proteins Mitofusins 1 and 2 (MFN1 and 2) and by the IMM protein Optic Atrophy 1 (OPA1). In humans, eight OPA1 isoforms are produced by alternative splicing of a single gene (Delettre et al., 2001) , which are further processed by at least three proteases to form several long (L) and short (S) forms of OPA1 (Anand et al., 2014; Ehses et al., 2009; Griparic et al., 2007; Head et al., 2009; Ishihara et al., 2006; Song et al., 2007) , which oligomerize to form functionally active quaternary structures (Frezza et al., 2006) . In addition to its role in mitochondrial fusion, OPA1 controls the cristae remodelling arm of mitochondrial apoptosis (Frezza et al., 2006) and the physical and functional organization of the MRC complexes in MRC supercomplexes (Cogliati et al., 2013) . These functional quaternary structures increase electron flow channelling through MRC complexes during respiration, thus minimizing electron leaks (Acin-Perez and Enriquez, 2014; Enriquez and Lenaz, 2014) , and stabilize individual MRC complexes such as Complex III, CIII (Acín-Pé rez et al., 2004) . Consequently, OPA1 levels directly affect mitochondrial respiratory efficiency (Cogliati et al., 2013) and proteolytic inactivation of OPA1 has been shown to occur in cells from mitochondrial disease patients (DuvezinCaubet et al., 2007) . However, the role of OPA1 in vivo and the potential of its stabilization as a strategy to combat mitochondrial dysfunction and disease remains unclear. Genetic ablation of Opa1 is lethal during mouse embryonic development (Rahn et al., 2013) and causes massive dysfunction also in postmitotic tissues (L.S., unpublished data). On the other hand, high levels of OPA1 overexpression are toxic in cells, leading to paradoxical mitochondrial fragmentation (Cipolat et al., 2004) . In order to avoid these effects, we have used X-chromosome-targeted Opa1 transgenesis (Opa1 tg ) to obtain moderate, ubiquitous overexpression in a mouse line (Cogliati et al., 2013) . Remarkably, Opa1 tg mice are fertile and viable, have normal lifespan, and are protected from a panoply of tissue insults, including denervation-induced skeletal muscle atrophy, brain and heart ischemiareperfusion damage, and liver failure caused by Fas-ligandinduced apoptosis (see the accompanying paper by Varanita et al., 2015) . We therefore reasoned that Opa1 overexpression could be exploited to correct the biochemical impairment and mitigate the pathology associated with genetically determined OXPHOS failure in available mouse models of mitochondrial disease. To this aim, we crossed the Opa1 tg mouse with (i) a constitutive knockout mouse for Ndufs4 (Ndufs4 -/-) ( Karamanlidis et al., 2013; Kruse et al., 2008; Quintana et al., 2010; Quintana et al., 2012) , encoding the 18 kDa subunit of complex I (cI), and (ii) a skeletal-muscle-specific knockout mouse for Cox15, in which the Cre-recombinase-driven ablation of Cox15 is dependent upon the muscle-specific actin gene promoter (Cox15 sm/sm ) (Viscomi et al., 2011) . Cox15 encodes a key enzyme in the biosynthesis of heme a, an essential catalytic redox component of complex IV ([CIV] ; cytochrome c oxidase [COX]) (Bareth et al., 2013; Barros et al., 2001; Barros and Tzagoloff, 2002; Glerum et al., 1997; Petruzzella et al., 1998; Wang et al., 2009) . In humans, mutations in NDUFS4 are associated with early-onset fatal Leigh syndrome due to severe Complex I (CI) deficiency (Petruzzella et al., 2001; Scacco et al., 2003; van den Heuvel et al., 1998) . Mutations in COX15 have been reported in children with severe isolated cardiomyopathy, encephalopathy, or cardioencephalomyopathy (Alfadhel et al., 2011; Antonicka et al., 2003; Bugiani et al., 2005) . Here we report that the mild Opa1 overexpression achieved in the Opa1 tg mice corrects these two models of CI and CIV deficiency, the latter to a greater extent. (Calvaruso et al., 2012; Kruse et al., 2008) . The Cox15 sm/sm mouse shows profound skeletal muscle COX deficiency, leading to muscle wasting, severe motor performance impairment, and markedly reduced survival (Viscomi et al., 2011) . Western blot analysis on two animals for each genotype showed tissue-specific increases in the levels of long and short forms of OPA1 in brain ( Figure S1A ), skeletal muscle ( Figure S1B ), and heart ( Figure S1C) 
RESULTS

Generation of Ndufs4
Ndufs4
-/-groups, each composed of six animals. However, the scores, which were identical in the two groups at the beginning of the observation (week 4 after birth), showed significant differences in subsequent measurements, with the Ndufs4
::Opa1 tg group performing consistently better than the Ndufs4 -/-group in weeks 5 (latency to fall: 556 ± 39 versus 388 ± 46 s) and 6 (latency to fall: 384 ± 56 versus 123 ± 50 s). At week 7, both groups were virtually unable to perform the test at any rate, due to collapse of neurological conditions or death ( Figure 1A ). Furthermore, Kaplan-Meier analysis showed that survival probability was moderately, but significantly, prolonged in Ndufs4 
-/-littermates (survival median: 62.0 versus 53.5 days; log-rank test p = 0.015) ( Figure 1B ). The amelioration in motor coordination and prolongation of the lifespan was associated with a $1.5-fold increase in glutamate-malate-dependent state-3 oxygen consumption rate of isolated brain mitochondria (reflecting CI-driven respiration), which nevertheless remained well below the values obtained in brain mitochondria of WT and Opa1 tg littermates ( Figure 1C ). Accordingly, CI activity, measured by spectrophotometric assay ( Figure 1D ), was $2. Figure S1D ). Western blot analysis using antibodies against NDUFB8 (specific to CI), UQCRC1 (specific to CIII), and COX1 (specific to CIV) showed, in the same genotypes, a catalytically active 200 kDa assembly intermediate as well as the catalytically inactive 830 kDa CI and 830 kDa+CIII 2 assembly intermediates previously reported in the Ndufs4
-/-mouse model (Calvaruso et al., 2012) , but neither CI holocomplex nor CI supercomplexes containing CI+CIII 2 or CI+CIII 2 +CIV ( Figure S1E ). However, electron microscopy analysis of forebrain ( Figure 1F ) and cerebellum (not shown) suggested amelioration in cristae architecture, with no change in mitochondrial shape and dimensions. These findings suggest that moderate Opa1 overexpression partially rescues the phenotype of a CI-deficient mouse model by improving cristae morphology. Figure 2A ). On average, the distance covered by Cox15 sm/sm ::Opa1 tg animals was three times that of the Cox15 sm/sm littermates (169 ± 20 versus 58 ± 6 m, p = 2.59 3 10 À6 ) ( Figure S2A ). This improvement was recorded in both homozygous females and hemizygous males, with no significant gender difference ( Figure S2B ). Interestingly, Opa1 Tg performed better than WT littermates (890 ± 50 versus 803 ± 27 m, p < 0.001; Figure S2A ). We followed the animals up to 6 months of age. Next, we performed ultrastructural analysis of muscle fibers ( Figure 4 ). Examination of tibialis anterior muscle revealed Figure 5A ). Similar results were obtained by measuring succinate-and TMPD/ascorbate-dependent state-3 oxygen consumption rate (reflecting CII-and CIV-driven respiration, respectively) ( Figure 5A ). We also analyzed the activity of the single respiratory complexes by spectrophotometric assays. Figure 6C ). Conversely, other mtDNA-(mt-Cox2) and nucleus-encoded (Cox4I1 and Cox5a) transcripts were unchanged in Cox15 sm/sm versus WT mice and were not affected by Opa1 overexpression ( Figure 6C ). We detected no quantitative change in any group of animals for transcripts Ppargc1a and Tfam, encoding PGC-1a and TFAM, respectively ( Figure 6C ). The mtDNA copy number, which was increased in Cox15 sm/sm , returned to WT levels in Cox15 sm/sm ::Opa1 tg ( Figure S3A ), suggesting normalization of the homeostatic control on mtDNA maintenance (Scarpulla et al., 2012 Figure S3B ), ruling out a direct effect of Opa1 overexpression on Cox15 transcription.
In order to analyze the composition and amount of OPA1, we performed a western blot experiment using an anti-OPA1 antibody that specifically recognizes five OPA1 species in skeletal muscle, namely isoforms 1 and 7, and short forms 1-3, resulting from proteolytic cleavage ( Figure 6A ). Densitometric quantification showed a significant increase ($1.4-fold) in the amount of all five detected OPA1 species in Opa1 tg muscle samples relative to WT. The amount of OPA1 species was further increased ($1.3-to 1.8-fold) in Cox15 sm/sm versus WT and significantly more so in Cox15 sm/sm ::Opa1 tg ($1.5-to 2-fold), particularly for the short forms 1-3 ( Figure S3C ).
These data suggest that Opa1 overexpression leads to stabilization in CIV protein and transcript levels. , 2004) . We therefore analyzed CI and CIV BNGE in-gel activities in digitonin-treated isolated muscle mitochondria. In Cox15 sm/sm samples, the intensity of the band corresponding to individual CIV holocomplex was markedly reduced, and hardly any reaction was detected in the high-molecular-weight area harboring sc. However, individual CIV in-gel activity was increased, and CIV reactive high-molecular-weight bands were clearly detected in Cox15 sm/sm ::Opa1 tg mitochondria ( Figure 7A ), indicating stabilization of CIV holocomplex and CIV-containing sc. Likewise, several high-molecular-weight CI-reactive bands, corresponding to CI-and CIV-containing sc, were virtually absent in the same Cox15 sm/sm samples but were clearly, albeit weakly, visible in the Cox15 sm/sm ::Opa1 tg samples ( Figure 7B ).
MRC Supercomplexes Are Increased in
Western blot analysis on BNGE samples using an anti-COX1-specific antibody confirmed the results of in-gel activity: a band corresponding to CIV holocomplex was increased in Cox15 sm/sm ::Opa1 tg compared to Cox15 sm/sm and high-molecular-weight Cox1-reactive bands, which were detected in WT and Figure 7D ).
These results indicate that increased OPA1 levels stabilize RCS and residual CIV in Cox15 sm/sm mice.
DISCUSSION
The moderate overexpression of Opa1 achieved in the Opa1 tg mouse model is well tolerated and compatible with normal development, fertility, and lifespan. No obvious detrimental effects were noted during the 6-month period of our experimental observation; although, as mentioned in the accompanying paper by Varanita et al. (2015) , prolonged Opa1 overexpression may lead to increased strain-specific prevalence of cancer, a somehow expected result given the antiapoptotic role of OPA1. However, increased OPA1 amount in key tissues, including skeletal and cardiac muscle, brain, and liver, confer remarkable protection against a wide spectrum of experimental tissue damage models (accompanying paper by Varanita et al., 2015) . Here, we demonstrate that this effect can be exploited to improve the motor performance, as well as biochemical and molecular phenotypes of two mouse models of genetically determined OXPHOS failure. The Ndufs4 -/-mouse is characterized by the complete absence of a structural component of CI. In the current map of mammalian CI, the NDUFS4 18 kDa subunit has been modeled into a density in a cleft between the 75 kDa subunit and the 49 kDa, 30 kDa, and NDUFB8 (TYKY) subunits (Vinothkumar et al., 2014) . This localization may explain why disease mutations in the 18 kDa subunit lead to accumulation of late-stage interrupted-assembly intermediates lacking the NADH-dehydrogenase module (Calvaruso et al., 2012 (Johnson et al., 2013) . However, the cristae-centric approach used here to treat CI deficiency improved survival to levels comparable to those achieved by every-other-day rapamycin administration (Johnson et al., 2013) . It would be interesting to verify if the combination of Opa1 overexpression and mTOR inhibition is additive and can achieve even better amelioration. We also cannot exclude that OPA1-driven correction of OXPHOS failure may be less amenable in brain than in other tissues, e.g., skeletal muscle. The Cox15 sm/sm mouse model is based on muscle-specific ablation of Cox15, dependent on the activity of the Cre recombinase under the control of the skeletal-muscle-specific actin promoter. Although Cox15 sm/sm animals display early-onset progressive mitochondrial myopathy, characterized by profound muscle weakness and wasting leading to early death, the genetic lesion underpinning this phenotype can be considered as a hypomorphic mutant allele, the effects of which on COX activity and MRC proficiency are severe but partial. Accordingly, Cox15 transcript was drastically decreased, but not absent, in Cox15 sm/sm and Cox15 sm/sm ::Opa1 tg muscles, explaining the presence of some residual COX activity in muscle of adult animals and the ''mosaic''-like distribution of the histochemical reaction to COX, which is preserved in scattered muscle fibers ( Figure 5C ). The molecular Cox15 sm/sm defect resembles that of the majority of mitochondrial disorders (i.e., partial rather than complete biochemical impairment) due to decreased but not abolished function of the mutant gene product. Incidentally, this category of mitochondrial diseases also includes the few COX15 mutant patients reported in the literature (Alfadhel et al., 2011; Antonicka et al., 2003; Bugiani et al., 2005) . These considerations may explain the marked and persistent improvement of the motor performance observed in Cox15 sm/sm ::Opa1 tg double mutants and suggest that OXPHOS impairment due to decreased, but not abolished, function of the mutant gene product is amenable to correction by potentiating the effects of OPA1 on mitochondrial cristae shape and MRC function.
The Cox15 sm/sm ::Opa1 tg animals displayed not only a dramatic increase in motor endurance but also a remarkable extension of survival up to, and in most cases well beyond, the 6-month period of observation of our experimental protocol. These effects were associated with robust increase of muscle mitochondrial respiration accompanied by a milder but significant increase of muscle COX activity. The discrepancy between the nearly complete reversion to normal in the respiratory rate and the modest increment of COX activity may be explained by increased stabilization of CIV holocomplex and CIV-associated supercomplexes, as indicated by results of BNGE in-gel activity and immunoblotting. The recovery in the motor performance and biochemical proficiency of the Cox15 sm/sm ::Opa1 tg double mutants was associated with marked correction of the profound ultrastructural alteration in cristae morphology associated with Cox15 ablation. This effect is likely to be directly connected to the role of OPA1 in cristae shape and may be correlated to partial stabilization of the CIV holocomplex and supercomplex organization in the cristae membrane. Accordingly, both nucleus-and mitochondria-encoded MRC subunits were increased in Cox15 sm/sm ::Opa1 tg versus Cox15 sm/sm muscles, while the corresponding transcripts were unchanged, with the notable exception of mt-Cox1 mRNA. COX1 is the mtDNA-encoded catalytic CIV subunit that contains the heme-a moieties essential for COX1 stabilization (Bareth et al., 2013) . The concordant decrease of both COX1 protein and mt-Cox1 mRNA in Cox15 sm/sm was completely reverted in Cox15 sm/sm ::Opa1 tg . Taken together, these results substantiate the possibility that in mammals, as in Saccharomyces cerevisiae, COX1 biosynthesis is regulated by a feedback mechanism linking translation and post-translation processing to transcription (Herrmann et al., 2013) . In yeast, a key role in this homeostatic loop is carried out by the mt-Cox1-specific translation activators MSS51 and PET309 (Herrmann et al., 2013) . The mammalian ortholog of PET309 has been identified as the leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein, an RNA binding factor that is mutated in French-Canadian, COX defective Leigh-like syndrome in humans (Mootha et al., 2003) . Interestingly, LRPPRC interacts with OPA1, at least in D. melanogaster (Banerjee and Chinthapalli, 2014) . However, as there is no obvious mammalian ortholog of MSS51, and the 5 0 UTR sequence of the yeast Cox1 mRNA, to which MSS51 binds, is virtually absent in the mammalian transcript, these feedback mechanisms are probably different in their molecular details between yeast and mammalian systems.
Finally, while apoptosis seems not to play a significant role in Cox15 sm/sm myopathy and is not increased in Cox15 sm/sm :: Opa1 tg samples, immunoanalysis suggested dysregulated autophagy in response to Cox15 ablation, but whether this is relevant to the pathogenesis of the disease remains to be further investigated.
Our study demonstrates that OPA1-dependent mitochondrial cristae and sc stabilization is effective in correcting mitochondrial disease conditions characterized by partial, however severe, MRC defects. OPA1 can even partially improve defects caused by complete lack of mitochondrial CI via an unknown mechanism. Our results indicate OPA1 as a new target for effective therapy of primary mitochondrial disorders. From a translational point of view, future work is warranted to elucidate the molecular details underpinning these remarkable effects, extend the experimental observation to additional OXPHOSdefective models, and eventually transfer this set of proof-ofprinciple observations into effective therapeutic approaches by, for example, selecting compounds or bioreactors able to control the expression or stability of OPA1 in suitable mammalian cell systems and animal models.
EXPERIMENTAL PROCEDURES
Reagents and Materials Antibodies (COX1, COX4, UQCRC2, NDUFA9, ATP5a, and SDHA) were from Mitoscience, GAPDH were from Millipore, P62 was from Sigma, LC3-I/II was from Cell Signaling, Lamp1 was from Sigma, and OPA1 was from BD Biosciences.
Animal Work
All procedures were conducted under the UK Animals (Scientific Procedures) Act, 1986, approved by Home Office license (PPL: 7538) and local ethical review. The mice were kept on a C57Bl6/129Sv mixed background, and WT littermates were used as controls. The animals were maintained in a temperature-and humidity-controlled animal-care facility with a 12 hr light/dark cycle and free access to water and food and were sacrificed by cervical dislocation.
Behavioral Analysis
A treadmill apparatus (Columbus Instruments) was used to measure motor exercise endurance according to the number of falls in the motivational grid during a gradually accelerating program with speed initially at 6.5 m/min and increasing by 0.5 m/min every 3 min. The test was terminated by exhaustion, defined as >10 falls/min into the motivational grid. A rotarod apparatus (Ugo Basile) was used to assess coordination skills. After two acclimation sessions, the mice underwent three trial sessions at least 20 min apart, using a standard acceleration protocol pre-set by the constructor.
Oxygen Consumption Studies
Mouse brains were homogenized in 0.075 M sucrose, 0.225 M mannitol, 1 mM EGTA, and 0.01% fatty-acids-free BSA (pH 7.4); skeletal muscle were homogenized in 150 mM sucrose, 50 mM Tris-HCl, 50 mM KCl, 10 mM EDTA, 0.2% BSA (pH 7.4), and subtilisin 1 mg/g of muscle (Frezza et al., 2007) . Mitochondria isolated by differential centrifugation and resuspended 25 mM sucrose, 75 mM sorbitol, 100 mM KCl, 0.05 mM EDTA, 5 mM MgCl 2 , 10 mM Tris-HCl (pH7.4), and 10 mM H 3 PO 4 (pH 7.4) (Ferná ndez-Vizarra et al., 2002) .
For oxygraphic measurements, 250-500 mg of mitochondrial proteins were incubated in a buffer containing 225 mM sucrose, 75 mM mannitol, 10 mM Tris-HCl (pH 7.4), 10 mM KCl, 10 mM KH 2 PO 4 , 5 mM MgCl 2 , and 1 mg/ml fatty-acids-free BSA (pH 7.4). Oxygen consumption was evaluated by a Clark oxygen electrode (Hansatech, Instruments), using the following substrates and inhibitors concentrations: 5 mM glutamate and 2.5 mM malate for cI-dependent respiration, 5 mM succinate and 2 mM rotenone for cII-dependent respiration, 6 mM ascorbate, and 300 mM TMPD and antimycin A 0.25 mg/ml for cIV-dependent respiration. 100 mM ADP was added to stimulate ATPcoupled oxygen consumption. 100 mM NaCN was added to completely inhibit respiration (Frezza et al., 2007) .
BNGE
For BNGE analysis, 250 mg of mitochondria isolated as described above were resuspended in native page buffer (Invitrogen), protease inhibitors, and 4% digitonin and incubated for 1 hr on ice before centrifuging at 20,000 3 g at 4 C. 5% Coomassie G250 was added to the supernatant. 30 mg were separated by 3%-12% gradient BNGE and either stained with for in-gel activities or electroblotted on PVDF membranes for immunodetection (Nijtmans et al., 2002) .
Morphological Analysis
For histochemical analysis, tissues were frozen in liquid-nitrogen-pre-cooled isopentane. 8-mm-thick sections were stained for COX and SDH, as described Sciacco and Bonilla (1996) . Analysis of centralized nuclei and analysis was performed on H&E-stained sections using ImageJ on four samples/genotype (600 fibers/sample). For ultrastructural studies, samples were fixed with 2.5% glutaraldehyde in 10 mM phosphate buffer (pH 7.4). Quantification of mitochondrial morphometry (area, perimeter, long axis, and short axis) in electron micrographs was performed using 
Biochemical Analysis of MRC Complexes
Brain and skeletal muscle samples were snap-frozen in liquid nitrogen and homogenized in 10 mM phosphate buffer (pH 7.4). The spectrophotometric activity of CI, CII, CIII, and CIV, as well as CS, was measured as described in Bugiani et al. (2004) .
Real-Time PCR
MtDNA content and transcripts analysis was carried out by SYBR Green realtime PCR, as described in Viscomi et al. (2011) .
Western Blot Analysis
Mouse tissues were homogenized in ten volumes of 10 mM potassium phosphate buffer (pH 7.4). Mitochondrial-enriched fractions were collected after centrifugation at 800 3 g for 10 min in the presence of protease inhibitors, and frozen and thawed three times in liquid nitrogen. Protein concentration was determined by the Lowry method. Aliquots, 70 mg each, were run through a 4%-12% SDS-PAGE and electroblotted onto a nitrocellulose membrane, which was then immunodecorated with different antibodies.
Statistical Analysis
All numerical data are expressed as mean ± SEM. Student's unpaired two-tail t test and Kaplan-Meier distribution were used for statistical analysis. Differences were considered statistically significant for p < 0.05.
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